pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Factors affecting SGLT2 inhibitor/metformin fixed dose combination prescription (multiple logistic regression analysis)

Characteristic Fixed dose combination

Adjusted OR 95% CI p value
Comorbidity
Hypertension
No 1 - -
Yes 0.92 0.79-1.08 0.299
Heart Failure
No 1 - -
Yes 1.06 0.74-1.50 0.750
Gastrointestinal disease
No 1 - -
Yes 0.92 0.78-1.08 0.352
Diabetic neuropathy
No 1 - -
Yes 0.76 0.62-0.93 0.008
Diabetic retinopathy
No 1 - -
Yes 0.81 0.64-1.01 0.066
Chronic Kidney Disease
No 1 - -
Yes 0.63 0.29-1.24 0.203
Institution
Tertiary hospital 1 - -
General hospital 1.40 1.06-1.85 0.019
Clinic 2.09 1.63-2.71 < 0.001
Others 1.21 0.82-1.79 0.320
Specialty
Internal medicine 1 - -
Family medicine 1.39 0.93-2.05 0.107
Others 1.44 0.89-2.30 0.131
Area
Seoul 1 - -
Kyeonggia 0.79 0.64-0.99 0.037
Gyeongsangb 0.77 0.61-0.97 0.025
Jeollac 1.16 0.87-1.55 0.314
Chungcheongd 0.68 0.51-0.90 0.007
Gangwon 1.21 0.77-1.91 0.404
Jeju 0.48 0.21-1.01 0.064
c stastic 0.60
p value of Hosmer-Lemshow test 0.21

OR, Odds Ratio; CI, Confidence Interval

a Kyeonggi-do and Incheon Metropolitan City are included

b Kyeongsangnam-do, Kyeongsangbu-do, Busan Metropolitan City, Ulsan Metropolitan City and Daegu Metropolitan City are included.

c Jeollanam-do, Jeollabuk-do and Gwangju Metropolitan City are included

d Chungcheongnam-do, Chungcheongbuk-do and Sejong City are included

Korean J Clin Pharm 2022;32:13-9 https://doi.org/10.24304/kjcp.2022.32.1.13
© 2022 Korean J Clin Pharm